Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Screening for novel antifungal drugs produced by actinomycetes.

FY 2013-14

Summary
Actinomycetes are soil bacteria that are an unparalleled source of structurally diverse small molecules. Their intrinsic production of therapeutically relevant compounds is contingent with activity against other organisms. These include but are not limited to antibiotics (vancomycin, amphotericin B), immunosuppressants (rapamycin) and anti-tumour agents (bleomycin). New antifungal drugs are desperately needed due to the current rise in antibiotic resistance which have depleted the reservoir of treatments that are available in the clinic. Today’s drug-screening tools have mostly resulted in the rediscovery of known compounds. Furthermore, their purification and structural elucidation can be a time-consuming process. To address this issue, my goal within the Nodwell lab will be to discover novel antifungal compounds produced by a unique collection of environmentally isolated actinomycetes by prioritizing non-purified extracts for their activity in other organisms. To accomplish this I have two specific aims: 1. To assess their activity spectrum and 2. To identify these cellular drug targets in crude extracts to determine how they work on a molecular level. My first aim will be to determine the microbial pathogens our extracts can inhibit. To carry this out, a panel of pathogenic fungi from Dr. Leah Cowen has been assembled. My preliminary results has shown that at least 5 crude extracts derived from two actinomycetes (WAC 248 and 262) inhibit the growth of two fungal pathogens Candida albicans and Cryptococcus neoformans that are comparable to standard clinical antifungal drugs. This can be used to prioritize extracts that will undergo a comprehensive chemical-genetic profiling screen. In Aim 2, I will conduct chemical-genetic profiling in the model fungi yeast to understand how these specific compounds function on a cellular level. This technique involves a comprehensive screen of a library of ~4,700 strains of yeast that have a specific gene deletion. If a strain has a deletion in a gene that confers sensitivity to the compound it suggests that the gene product is involved in the antifungal’s mode of action. Using this technique I will compare the extract’s profile to a compendium of known antifungals that have been previously generated by members of Dr. Charlie Boone’s laboratory. Preliminary data with extracts that I have generated from two actinomycete strains WAC 248 and 262 have been carried out in a short period of time which has shown that this technique is possible on a larger scale. I will then seek to scale up this screen to involve a collection of extracts derived from multiple rare actinomycetes that have been collected by Dr. Gerry Wright's laboratory. The implications of having new compounds that can be prioritized for purification are astronomic. My overall goal will be to compile a set of molecules that can be used not only as potent antibiotics, but also have unique utilities that could transform the paradigms in specific fields of biomedical science.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311870
Name
Ho Louis K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Screening for novel antifungal drugs produced by actinomycetes.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Actinomycetes; Antibiotics; Bacteria; Chemical Genetics; Drug Discovery; Fungi; Natural Products; Screening; Streptomyces; Yeast
Abstract
Actinomycetes are soil bacteria that are an unparalleled source of structurally diverse small molecules. Their intrinsic production of therapeutically relevant compounds is contingent with activity against other organisms. These include but are not limited to antibiotics (vancomycin, amphotericin B), immunosuppressants (rapamycin) and anti-tumour agents (bleomycin). New antifungal drugs are desperately needed due to the current rise in antibiotic resistance which have depleted the reservoir of treatments that are available in the clinic. Today’s drug-screening tools have mostly resulted in the rediscovery of known compounds. Furthermore, their purification and structural elucidation can be a time-consuming process. To address this issue, my goal within the Nodwell lab will be to discover novel antifungal compounds produced by a unique collection of environmentally isolated actinomycetes by prioritizing non-purified extracts for their activity in other organisms. To accomplish this I have two specific aims: 1. To assess their activity spectrum and 2. To identify these cellular drug targets in crude extracts to determine how they work on a molecular level. My first aim will be to determine the microbial pathogens our extracts can inhibit. To carry this out, a panel of pathogenic fungi from Dr. Leah Cowen has been assembled. My preliminary results has shown that at least 5 crude extracts derived from two actinomycetes (WAC 248 and 262) inhibit the growth of two fungal pathogens Candida albicans and Cryptococcus neoformans that are comparable to standard clinical antifungal drugs. This can be used to prioritize extracts that will undergo a comprehensive chemical-genetic profiling screen. In Aim 2, I will conduct chemical-genetic profiling in the model fungi yeast to understand how these specific compounds function on a cellular level. This technique involves a comprehensive screen of a library of ~4,700 strains of yeast that have a specific gene deletion. If a strain has a deletion in a gene that confers sensitivity to the compound it suggests that the gene product is involved in the antifungal’s mode of action. Using this technique I will compare the extract’s profile to a compendium of known antifungals that have been previously generated by members of Dr. Charlie Boone’s laboratory. Preliminary data with extracts that I have generated from two actinomycete strains WAC 248 and 262 have been carried out in a short period of time which has shown that this technique is possible on a larger scale. I will then seek to scale up this screen to involve a collection of extracts derived from multiple rare actinomycetes that have been collected by Dr. Gerry Wright's laboratory. The implications of having new compounds that can be prioritized for purification are astronomic. My overall goal will be to compile a set of molecules that can be used not only as potent antibiotics, but also have unique utilities that could transform the paradigms in specific fields of biomedical science.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ho, Louis K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~